{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:03:18Z","timestamp":1785488598591,"version":"3.56.0"},"reference-count":81,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science, Technological Development and Innovation of the Republic of Serbia","award":["451-03-33\/2026-03\/200015"],"award-info":[{"award-number":["451-03-33\/2026-03\/200015"]}]},{"award":["451-03-33\/2026-03\/200015"],"award-info":[{"award-number":["451-03-33\/2026-03\/200015"]}],"id":[{"id":"https:\/\/ror.org\/01znas443","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Background\/Objectives: Multiple myeloma (MM) is an incurable, hematological malignancy caused by the abnormal proliferation of terminally differentiated plasma cells in the bone marrow. Current research indicates that N-azacytidine, as an epigenetic drug and nucleoside metabolic inhibitor, can be efficient in MM treatment. However, data on bone marrow mesenchymal stromal cells (BMSCs), as a critical cell population in the hematopoiesis and bone remodeling processes, are limited. Methods: The effect of N-azacytidine on the myeloma cell line AMO-1, bone marrow mesenchymal stromal cells from MM patients (MM-MSCs) and patients undergoing hip arthroplasty (BMSCs) as a healthy control in hypoxia (3% O2) were examined. Cellular functions such as viability, proliferation, phenotype, and differentiation were determined by in vitro tests and flow-cytometry. Results: N-azacytidine (100 nM to 1000 nM) significantly inhibited metabolic activity, cell cycle, CFSE dilution and CD138+\/CD38+ expression levels by myeloma cells after 72 h. No viability changes were detected in MM-MSCs and BMSCs treated with N-azacytidine. As for both BMSCs and MM-MSCs differentiation potential, N-azacytidine did not affect alkaline phosphatase (ALP) activity and adipogenesis but inhibited matrix mineralization (500 nM and 1000 nM). However, when BMSCs were pretreated with N-azacytidine for 72 h, changes in ALP activity and mineralization level were not detected. Conclusions: N-azacytidine, along with the suppressive effect on myeloma cells, did not change the differentiation potential of MSCs, but rather preserved their capacity. These findings are of particular importance considering MM progression and bone tissue destruction, suggesting that N-azacytidine may represent a promising therapeutic agent for myeloma disease.<\/jats:p>","DOI":"10.3390\/metabo16080540","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:46:41Z","timestamp":1785487601000},"page":"540","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["N-Azacytidine Inhibits Myeloma Cell Growth While Preserving Multiple Myeloma Patient Derived-Bone Marrow Mesenchymal Stromal Cells Differentiation"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3174-4358","authenticated-orcid":false,"given":"Tamara","family":"Kukolj","sequence":"first","affiliation":[{"name":"Group for Hematology and Stem Cells, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia"},{"name":"Center for Solid State Physics and New Materials, Institute of Physics, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anica","family":"Spasi\u0107","sequence":"additional","affiliation":[{"name":"Group for Hematology and Stem Cells, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1050-378X","authenticated-orcid":false,"given":"Dragana","family":"Aleksandrovi\u0107","sequence":"additional","affiliation":[{"name":"Group for Hematology and Stem Cells, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Bogosavljevi\u0107","sequence":"additional","affiliation":[{"name":"Institute for Orthopaedics Banjica, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Vuja\u010di\u0107","sequence":"additional","affiliation":[{"name":"Institute for Orthopaedics Banjica, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mila","family":"Puri\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Jaukovi\u0107","sequence":"additional","affiliation":[{"name":"Group for Hematology and Stem Cells, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drenka","family":"Trivanovi\u0107","sequence":"additional","affiliation":[{"name":"Group for Hematology and Stem Cells, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Padala, S.A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., and Ajebo, G.H. (2021). Epidemiology, Staging, and Management of Multiple Myeloma. Med. Sci., 9.","DOI":"10.3390\/medsci9010003"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100668","DOI":"10.1016\/j.jbo.2025.100668","article-title":"Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives","volume":"51","author":"Lungu","year":"2025","journal-title":"J. Bone Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103920","DOI":"10.1016\/j.sjbs.2023.103920","article-title":"An overview of multiple myeloma: A monoclonal plasma cell malignancy\u2019s diagnosis, management, and treatment modalities","volume":"31","author":"Abduh","year":"2024","journal-title":"Saudi J. Biol. Sci."},{"key":"ref_7","first-page":"573","article-title":"The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward","volume":"17","author":"Ram","year":"2024","journal-title":"Pharmacogenomics Pers. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bone.2015.02.021","article-title":"Dynamic interplay between bone and multiple myeloma: Emerging roles of the osteoblast","volume":"75","author":"Reagan","year":"2015","journal-title":"Bone"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: From bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4236\/jct.2014.54045","article-title":"Biology and Treatment of Skeletal Manifestations in Multiple Myeloma","volume":"5","author":"Stavropoulos","year":"2014","journal-title":"J. Cancer Ther."},{"key":"ref_11","first-page":"2207","article-title":"Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma","volume":"109","author":"Shin","year":"2024","journal-title":"Haematologica"},{"key":"ref_12","first-page":"e74970","article-title":"Advancements in the Treatment of Multiple Myeloma","volume":"16","year":"2024","journal-title":"Cureus."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100808","DOI":"10.1016\/j.blre.2021.100808","article-title":"Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options","volume":"49","author":"Ramasamy","year":"2021","journal-title":"Blood Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1178224219868235","DOI":"10.1177\/1178224219868235","article-title":"Multiple myeloma: An overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat. Care Soc. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Geraldes, C., Roque, A., Sarmento-Ribeiro, A.B., Neves, M., Ionita, A., Gerivaz, R., Tom\u00e9, A., Afonso, S., Silveira, M.P., and Sousa, P. (2024). Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1282300"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10238-025-01783-z","article-title":"The epigenetic revolution in hematology: From benchside breakthroughs to clinical transformations","volume":"25","author":"Esfahani","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13148-021-01069-7","article-title":"Advances in epigenetic therapeutics with focus on solid tumors","volume":"13","author":"Jin","year":"2021","journal-title":"Clin. Epigenet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.seminhematol.2020.12.004","article-title":"DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"58","author":"Khouri","year":"2021","journal-title":"Semin. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/10428194.2025.2606209","article-title":"Combination therapy of BCL-2 antagonist venetoclax and demethylase inhibitor azacitidine for the treatment of multiple myeloma: A clinical study","volume":"7","author":"Wang","year":"2026","journal-title":"Leuk. Lymphoma"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ijc.35426","article-title":"Epigenetic reprogramming in multiple myeloma-Challenges and opportunities","volume":"158","author":"Kumar","year":"2026","journal-title":"Int. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3324\/haematol.12261","article-title":"The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma","volume":"93","author":"Khong","year":"2008","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1477-5956-11-24","article-title":"Azacytidine induces necrosis of multiple myeloma cells through oxidative stress","volume":"11","author":"Tian","year":"2013","journal-title":"Proteome Sci."},{"key":"ref_23","first-page":"110","article-title":"Inductive Effect of 5-Azacitidine on Apoptosis of Multiple Myeloma Cell lines and Its Mechanism","volume":"24","author":"Wang","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/bloodadvances.2018022053","article-title":"Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis","volume":"2","author":"Wenk","year":"2018","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/bjh.18783","article-title":"Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial","volume":"201","author":"Menezes","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Lehner, K.M., Gopalakrishnapillai, A., Kolb, E.A., and Barwe, S.P. (2023). Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A Rearranged Pediatric AML Is Overcome by Azacitidine\u2013Panobinostat Combination. Cancers, 15.","DOI":"10.3390\/cancers15123112"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.it.2013.10.002","article-title":"Regulation of hematopoietic stem cells by bone marrow stromal cells","volume":"35","author":"Anthony","year":"2014","journal-title":"Trends Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.imlet.2015.06.020","article-title":"BMSCs and hematopoiesis","volume":"168","year":"2015","journal-title":"Immunol. Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1540148","DOI":"10.1155\/2018\/1540148","article-title":"The Differentiation Balance of Bone Marrow Mesenchymal Stem Cells Is Crucial to Hematopoiesis","volume":"2018","author":"Wu","year":"2018","journal-title":"Stem Cells Int."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ria, R., and Vacca, A. (2020). Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020613"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41467-020-20715-x","article-title":"Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease","volume":"12","author":"Li","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1038\/s41467-024-47793-5","article-title":"Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes","volume":"15","author":"Binder","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/stemcells.2005-0220","article-title":"A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: A potential role in the development of lytic bone disease and tumor progression in multiple myeloma","volume":"24","author":"Gunn","year":"2006","journal-title":"Stem Cells"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1158\/0008-5472.CAN-11-2067","article-title":"Bone marrow stromal cells create a permissive microenvironment for myeloma development: A new stromal role for Wnt inhibitor Dkk1","volume":"72","author":"Fowler","year":"2012","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4252\/wjsc.v6.i3.322","article-title":"Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics","volume":"6","author":"Garayoa","year":"2014","journal-title":"World J. Stem Cells."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Heinemann, L., M\u00f6llers, K.M., Ahmed, H.M.M., Wei, L., Sun, K., Nimmagadda, S.C., Frank, D., Baumann, A., Poos, A.M., and Dugas, M. (2022). Inhibiting PI3K-AKT-mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.874325"},{"key":"ref_37","first-page":"431","article-title":"Azacitidine: Mechanisms of action in the treatment of hematologic malignancies","volume":"36","author":"Khan","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1038\/bcj.2014.14","article-title":"5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies","volume":"4","author":"Gang","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-022-00615-7","article-title":"Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients","volume":"12","author":"Grimm","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ebelt, N.D., and Manuel, E.R. (2023). 5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15010118"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100805","DOI":"10.1016\/j.drup.2022.100805","article-title":"Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia","volume":"61","author":"Janotka","year":"2022","journal-title":"Drug Resist Updat."},{"key":"ref_42","first-page":"2930","article-title":"Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma","volume":"109","author":"Flanagan","year":"2024","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1038\/s41375-020-0785-1","article-title":"Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis","volume":"34","author":"Sarin","year":"2020","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1158\/1535-7163.MCT-07-0010","article-title":"5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells","volume":"6","author":"Kiziltepe","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.18632\/oncotarget.26784","article-title":"The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes","volume":"10","author":"Murakami","year":"2019","journal-title":"Oncotarget"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"31568","DOI":"10.1038\/s41598-025-17093-z","article-title":"Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation","volume":"15","author":"Nylund","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5045\/kjh.2012.47.4.239","article-title":"Phenotypic consensus markers for plasma cell myeloma","volume":"47","author":"Hur","year":"2012","journal-title":"Korean J. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Costa, F., Dalla Palma, B., and Giuliani, N. (2019). CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents. Cells., 8.","DOI":"10.3390\/cells8121632"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3892\/ijo.2012.1545","article-title":"Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide","volume":"41","author":"Kawano","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3892\/ijo.2013.2134","article-title":"Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells","volume":"43","author":"Kawano","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"van de Donk, N.W.C.J., and Usmani, S.Z. (2018). CD38 antibodies in multiple myeloma: Mechanisms of action and modes of resistance. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02134"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Riccardi, F., Tangredi, C., Dal Bo, M., and Toffoli, G. (2024). Targeted therapy for multiple myeloma: An overview on CD138-based strategies. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1370854"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Horenstein, A.L., Bracci, C., Morandi, F., and Malavasi, F. (2019). CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00760"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Becherini, P., Soncini, D., Ravera, S., Gelli, E., Martinuzzi, C., Giorgetti, G., Cagnetta, A., Guolo, F., Ivaldi, F., and Miglino, M. (2023). CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents. Antioxidants., 12.","DOI":"10.3390\/antiox12020494"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2017-01-761643","article-title":"CD138 mediates selection of mature plasma cells by regulating their survival","volume":"129","author":"McCarron","year":"2017","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.13927","article-title":"A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma","volume":"173","author":"Muz","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Morandi, F., Horenstein, A.L., Costa, F., Giuliani, N., Pistoia, V., and Malavasi, F. (2018). CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02722"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41375-021-01355-6","article-title":"Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab","volume":"36","author":"Doose","year":"2022","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/cyto.b.21869","article-title":"Multiple myeloma with CD138 changed from positive to negative: A case report","volume":"100","author":"Yu","year":"2021","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1078-0432.CCR-11-2212","article-title":"Multiple myeloma mesenchymal stem cells: Characterization, origin, and tumor-promoting effects","volume":"18","author":"Reagan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41375-018-0061-9","article-title":"Mesenchymal stem cells in multiple myeloma: A therapeutical tool or target?","volume":"32","author":"Xu","year":"2018","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12935-025-03741-x","article-title":"Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: A double-edged sword","volume":"25","author":"Kamrani","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Wang, L., Yi, W., Ma, L., Lecea, E., Hazlehurst, L.A., Adjeroh, D.A., and Hu, G. (2023). Inflammatory Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma: Transcriptional Signature and In Vitro Modeling. Cancers, 15.","DOI":"10.3390\/cancers15215148"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/15569543.2013.846382","article-title":"5-Azacytidine inhibits proliferation and induces apoptosis of mouse bone marrow-derived mesenchymal stem cells","volume":"32","author":"Zhang","year":"2013","journal-title":"Toxin Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"203659","DOI":"10.1016\/j.cdev.2021.203659","article-title":"5-Azacytidine pretreatment confers transient upregulation of proliferation and stemness in human mesenchymal stem cells","volume":"165","author":"Ong","year":"2021","journal-title":"Cells Dev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10616-009-9203-2","article-title":"5-Azacytidine facilitates osteogenic gene expression and differentiation of mesenchymal stem cells by alteration in DNA methylation","volume":"60","author":"Zhou","year":"2009","journal-title":"Cytotechnology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12195-020-00654-9","article-title":"Effect of the Addition Frequency of 5-Azacytidine in Both Micro- and Macroscale Cultures","volume":"14","author":"Kadekar","year":"2020","journal-title":"Cell. Mol. Bioeng."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/jcmm.12972","article-title":"The effects of the DNA methyltranfserases inhibitor 5-Azacitidine on ageing, oxidative stress and DNA methylation of adipose derived stem cells","volume":"21","author":"Kornicka","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Maiso, P., Mogoll\u00f3n, P., Ocio, E.M., and Garayoa, M. (2021). Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression. Cancers, 13.","DOI":"10.3390\/cancers13112542"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2891957","DOI":"10.1155\/2018\/2891957","article-title":"The Mechanobiology of the Actin Cytoskeleton in Stem Cells during Differentiation and Interaction with Biomaterials","volume":"2018","author":"Ambriz","year":"2018","journal-title":"Stem Cells Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"235","DOI":"10.21873\/invivo.14187","article-title":"5-Azacytidine Enhances Differentiation of Human Placenta-derived Mesenchymal Stem Cells Towards Schwann-like Cells","volume":"40","author":"Sotthibundhu","year":"2026","journal-title":"In Vivo"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"22","DOI":"10.21037\/sci-2020-007","article-title":"DNA methyltransferase inhibitor 5-azacytidine in high dose promotes ultrastructural maturation of cardiomyocyte","volume":"7","author":"Saheli","year":"2020","journal-title":"Stem Cell Investig."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/scd.2010.0519","article-title":"5-Azacytidine induces cardiac differentiation of human umbilical cord-derived mesenchymal stem cells by activating extracellular regulated kinase","volume":"21","author":"Qian","year":"2012","journal-title":"Stem Cells Dev."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Yan, X., Ehnert, S., Culmes, M., Bachmann, A., Seeliger, C., Schyschka, L., Wang, Z., Rahmanian-Schwarz, A., St\u00f6ckle, U., and De Sousa, P.A. (2014). 5-azacytidine improves the osteogenic differentiation potential of aged human adipose-derived mesenchymal stem cells by DNA demethylation. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090846"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5045\/br.2017.52.1.18","article-title":"Enhanced differentiation of mesenchymal stromal cells by three-dimensional culture and azacitidine","volume":"52","author":"Bae","year":"2017","journal-title":"Blood Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1038\/s41598-021-85122-8","article-title":"Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression","volume":"11","author":"Weickert","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Wu, Y., Aanei, C.M., Kesr, S., Picot, T., Guyotat, D., and Campos Catafal, L. (2017). Impaired Expression of Focal Adhesion Kinase in Mesenchymal Stromal Cells from Low-Risk Myelodysplastic Syndrome Patients. Front. Oncol., 7.","DOI":"10.3389\/fonc.2017.00164"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Ceccarelli, S., Gerini, G., Megiorni, F., Pontecorvi, P., Messina, E., Camero, S., Anastasiadou, E., Romano, E., Onesti, M.G., and Napoli, C. (2022). Inhibiting DNA methylation as a strategy to enhance adipose-derived stem cells differentiation: Focus on the role of Akt\/mTOR and Wnt\/\u03b2-catenin pathways on adipogenesis. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.926180"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s11658-021-00259-8","article-title":"Actin polymerization state regulates osteogenic differentiation in human adipose-derived stem cells","volume":"26","author":"Sun","year":"2021","journal-title":"Cell. Mol. Biol. Lett."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/8\/540\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:49:28Z","timestamp":1785487768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/8\/540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":81,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["metabo16080540"],"URL":"https:\/\/doi.org\/10.3390\/metabo16080540","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]}}}